Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCALATE-RT: Enzalutamide + ADT with or without Radiotherapy in Oligometastatic Prostate Cancer
NCT07782112Phase 3Not yet recruiting
- Sponsor
- Ente Ospedaliero Cantonale
- Start
- Nov 2026
- Primary completion
- Jul 2030
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Ente Ospedaliero Cantonale. Primary endpoint: Time to first re-initiation of treatment at 5 years. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07782112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07782112.